Engle Capital Management L.P. purchased a new stake in agilon health, inc. (NYSE:AGL – Get Rating) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 486,000 shares of the company’s stock, valued at approximately $11,382,000. agilon health makes up about 3.3% of Engle Capital Management L.P.’s investment portfolio, making the stock its 12th biggest holding. Engle Capital Management L.P. owned about 0.12% of agilon health at the end of the most recent reporting period.
→ Traders Rave: This Is The Best Play For Options! (From Tradewins)
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC grew its holdings in shares of agilon health by 14.9% during the second quarter. FMR LLC now owns 34,862,287 shares of the company’s stock worth $761,043,000 after purchasing an additional 4,512,008 shares during the last quarter. Wellington Management Group LLP raised its position in agilon health by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company’s stock valued at $470,953,000 after buying an additional 1,834,890 shares during the last quarter. Vanguard Group Inc. raised its position in agilon health by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 13,235,600 shares of the company’s stock valued at $335,522,000 after buying an additional 177,239 shares during the last quarter. Capital Research Global Investors grew its stake in agilon health by 18.4% in the 1st quarter. Capital Research Global Investors now owns 9,867,875 shares of the company’s stock valued at $250,151,000 after purchasing an additional 1,536,506 shares during the period. Finally, Brown Advisory Inc. grew its stake in agilon health by 1.4% in the 3rd quarter. Brown Advisory Inc. now owns 3,695,284 shares of the company’s stock valued at $86,543,000 after purchasing an additional 50,416 shares during the period.
Insider Transactions at agilon health
In other news, insider Benjamin Shaker sold 28,555 shares of the business’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $23.37, for a total value of $667,330.35. Following the completion of the transaction, the insider now owns 25,625 shares in the company, valued at $598,856.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Benjamin Kornitzer sold 2,698 shares of agilon health stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $15.51, for a total value of $41,845.98. Following the completion of the sale, the insider now owns 10,426 shares of the company’s stock, valued at $161,707.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin Shaker sold 28,555 shares of the business’s stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $23.37, for a total value of $667,330.35. Following the sale, the insider now directly owns 25,625 shares of the company’s stock, valued at approximately $598,856.25. The disclosure for this sale can be found here. Insiders sold 68,168 shares of company stock worth $1,413,444 over the last quarter. 3.30% of the stock is currently owned by insiders.
agilon health Trading Down 2.3 %
Shares of AGL stock traded down $0.55 during mid-day trading on Friday, hitting $23.03. The company’s stock had a trading volume of 412,808 shares, compared to its average volume of 1,925,940. agilon health, inc. has a 52-week low of $14.82 and a 52-week high of $28.36. The business has a 50-day moving average price of $19.16 and a 200 day moving average price of $20.46. The company has a quick ratio of 2.48, a current ratio of 2.48 and a debt-to-equity ratio of 0.04.
Wall Street Analyst Weigh In
AGL has been the subject of several research reports. SVB Leerink cut their price target on agilon health from $33.00 to $30.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. Wells Fargo & Company reduced their price target on agilon health from $28.00 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 15th. Stifel Nicolaus began coverage on agilon health in a research report on Thursday, December 8th. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, The Goldman Sachs Group cut their price objective on agilon health from $38.00 to $34.00 and set a “buy” rating on the stock in a research report on Tuesday, November 15th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, agilon health currently has a consensus rating of “Moderate Buy” and an average price target of $28.38.
agilon health Company Profile
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.
Recommended Stories
Want to see what other hedge funds are holding AGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for agilon health, inc. (NYSE:AGL – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider agilon health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and agilon health wasn’t on the list.
While agilon health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
